In a research report sent to investors today, Brean Capital analyst Difei Yang maintained a Buy rating on Osiris Therapeutics (NASDAQ:OSIR) with a $19 price target, following a one on one meeting with Osiris CEO, Dr. Lode Debrabandere.
Yang wrote, “Our key takeaways are: 1). While Osiris believes it is still early in the development of skin substitute market, the growth rate we have seen during 2013-2014 may not be typical; 2). The wound care market is still largely a relationship-driven market; 3). A top priority for Osiris in 2015 is to secure insurance coverage from private payors for Grafix while benefiting from the recent sales force expansion. In addition, the CEO is actively looking to in-license a second product to leverage the sales force 4). Given the ongoing OIG (Office of Inspector General) investigation at competitor Mimedix, we are increasingly confident that the company is likely to outperform in 2015 both from market expansion and market share gains from competitors. Depending on how the launch goes at Stryker on viable bone matrix BIO4, there could be meaningful upside to our 2015 revenue forecast.”
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing products to treat medical conditions in wound care, orthopedic, and sports medicine markets.